Biocon, Asia’s leading biotechnology enterprise, has reportedly received India marketing rights for Roche’s cancer drug clone. The cancer drug has market of around $6 billion globally. Moreover, the company is likely to market Roche’s cancer drug clone by end of FY14.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.